Molecular mechanisms of the microRNA-132 during tumor progressions

Abstract

Cancer as one of the leading causes of human deaths has always been one of the main health challenges in the world. Despite recent advances in therapeutic and diagnostic methods, there is still a high mortality rate among cancer patients. Late diagnosis is one of the main reasons for the high ratio of cancer related deaths. Therefore, it is required to introduce novel early detection methods. Various molecular mechanisms are associated with the tumor progression and metastasis. MicroRNAs (miRNAs) are a class of non-coding RNAs (ncRNAs) family that has important functions in regulation of the cellular processes such as cell proliferation, apoptosis, and tumor progression. Moreover, they have higher stability in body fluids compared with mRNAs which can be introduced as non-invasive diagnostic markers in cancer patients. MiR-132 has important functions as tumor suppressor or oncogene in different cancers. In the present review, we have summarized all of the studies which have been reported the role of miR-132 during tumor progressions. We categorized the miR-132 target genes based on their cell and molecular functions. Although, it has been reported that the miR-132 mainly functions as a tumor suppressor, it has also oncogenic functions especially in pancreatic tumors. MiR-132 mainly exerts its roles during tumor progressions by regulation of the transcription factors and signaling pathways. Present review clarifies the tumor specific molecular mechanisms of miR-132 to introduce that as an efficient non-invasive diagnostic marker in various cancers.

Background

Cancer is one of the main causes of human deaths worldwide, with an estimated 10.0 million deaths in 2020 [1]. It is the second leading cause of mortality in the United States with about 606,520 deaths in 2020 [2, 3]. The financial burden of cancer poses different challenges for the patients and healthcare system [4]. As the morphologically similar tumors may exhibit different clinical symptoms due to their molecular differences, it is of high importance to introduce non-invasive methods to assess the molecular differences in tumors to select the most efficient therapeutic option. As the non-protein-coding DNA covers almost 97% of the human genome, non-coding RNAs (ncRNAs) have become the frontier of cancer biology [5, 6]. They are categorized into the various families such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs), small interfering RNAs (siRNAs), and circular RNA (circRNA) [7,8,9]. MiRNAs are a class of the short ncRNAs involved in post-transcriptional regulation through binding to 3 untranslated region (3-UTR) of the target mRNA that results in mRNA degradation or translational inhibition [10]. Considering, the crucial functions of miRNAs in regulation of cellular mechanisms including cell proliferation, differentiation, growth, and apoptosis [11, 12], aberrant miRNA expression can be correlated with various cancers [13]. MiRNAs may serve as tumor suppressors, oncogenes, and regulators of the self-renewal process in cancer stem cells (CSC) [14]. Dysregulated miRNAs are promising diagnostic tumor markers and are also efficient as novel targets for the cancer therapy [15]. Since, they have higher stability in body fluids compared with mRNAs, the expression profiling of circulating miRNAs in body fluids can be utilized as a non-invasive method for cancer diagnosis and prognosis [16,17,18,19,20]. MiR-132 is a critical regulator of various cellular processes such as angiogenesis, cell proliferation, migration, and apoptosis [21,22,23]. Aberrant expression of miR-132 has been frequently reported in various cancers. It functions as a tumor suppressor or oncogene in different cancers [24,25,26,27]. Therefore, we have summarized all of the studies which have been reported the role of miR-132 during tumor progressions. We categorized the miR-132 target genes based on their cell and molecular functions (Table 1).

Table 1 Molecular targets of miR-132 during tumor progressions

Transcription factors

Forkhead box proteins (Fox) transcription factors

There are increasing numbers of the feedback loop interactions between transcription factors and miRNAs in which the transcription factors up or down regulate the miRNAs, while the miRNAs inhibit the transcription factors in a negative feedback [28]. FOXO1 belongs to the Forkhead box proteins (Fox) transcription factors that functions as a negative regulator of cell cycle progression [29]. It has been shown that miR-132 significantly promoted gastric tumor cell growth by FOXO1 targeting. There was also significant miR-132 up regulation in gastric cancer (GC) tissues in comparison with normal margins [30]. Forkhead box protein A1 (FOXA1) is a pivotal transcription factor involved in cell proliferation, apoptosis, and differentiation, organogenesis, and tumor progression [31, 32]. It is required for the chromatin recruitment of estrogen receptor that regulates chromatin remodeling, estrogen receptor-related gene expressions, and tumor cell proliferation [33, 34]. It has been shown that there was an inverse correlation between the levels of miR-132 and FOXA1 expressions. MiR-132 reduced the breast tumor cells proliferation via FOXA1 targeting [35]. There was also miR-132 down regulation in thyroid tumor tissues and cell lines. It reduced thyroid tumor cell proliferation and invasion by FOXA1 inhibition [36]. Cisplatin (CDPP) is one of the main therapeutic drugs in nasopharyngeal carcinoma (NPC), however there is a noticeable ratio of resistance among the patients [37]. It has been reported that there was miR-132 down regulation in NPC patients. It also induced CDDP sensitivity in NPC cells through FOXA1 suppression [32]. Long non-coding RNAs (lncRNAs) are a family of the ncRNAs that regulate cell growth and tumorigenesis by post-transcriptional regulation and miRNAs sponging [38]. They are involved in tumorigenesis, tissue development, embryogenesis, and inflammation [39,40,41]. Pseudogene belongs to the lncRNAs family that regulates the gene expression during tumor progressions. PTTG3P is a pseudogene that is up regulated in pancreatic ductal adenocarcinoma (PDAC) tissues. It has been observed that there were correlations between the PTTG3P up regulation, larger tumor size, poor prognosis, and poor differentiation in PDAC tissues. PTTG3P induced tumor growth and invasion through miR-132-3p sponging that resulted in FOXM1 targeting [42]. It has been observed that there were LINC01551 up regulation in NPC tissues and cells. LINC01551 induced malignant transformation of NPC by miR-132-5p sponging [43].

Developmental transcription factors

SOX5 belongs to the Sox family of developmental transcription factors involved in regulation of embryogenesis, cell differentiation, proliferation, and migration [44]. There were miR-132 down regulations in invasive pituitary tumor tissues and cell lines. It reduced cell proliferation and invasion through SOX5 suppression [45]. Circular RNAs (CircRNAs) are endogenous RNAs characterized by closed continuous loops without polyadenylated tail [46]. They are involved in different cellular mechanisms such as chromatin remodeling, cell proliferation, apoptosis, invasion, and differentiation [47, 48]. It has been observed that there was circDOCK1 up regulation in bladder cancer (BCa) cells. CircDOCK1 induced cell proliferation and migration by miR‐132‐3p sponging that resulted in SOX5 up regulation [49]. SOX2 is a developmental transcription factor that participates in self-renewal process and tumor progression [50]. NEAT1 sponged miR-132 to up regulate SOX2 in glioma cells [51]. Epithelial-mesenchymal transition (EMT) is a pivotal process during tumor progression in which the tumor cells lose their epithelial feature and cell–cell adhesion to gain mesenchymal feature with high migratory and invasive properties [52,53,54]. EMT is orchestrated by various structural factors such as CDH1 and VIM that are regulated by EMT-related transcription factors including SNAI1, SNAI2, and TWIST [55,56,57]. SOX4 is a developmental transcription factor with critical functions during embryogenesis and tumorigenesis. It has been shown that miR-132 reduced osteosarcoma (OS) cell proliferation and EMT via SOX4 targeting. There was a miR-132 down regulation in OS cell lines in comparison with normal cells. It also regulated apoptosis by BCL-2 targeting. Moreover, miR-132 significantly inhibited OS invasion by CDH1 up regulation, while down regulation of the mesenchymal factors such as CDH2 and VIM [58]. SOX4 has a critical role in promotion of EMT process during the prostate cancer (PCa) progression [59]. There was a significant association between miR-132 down regulation, high Gleason score, and distant metastasis. MiR-132 inhibited prostate tumor cell migration, colony formation, and TGF-b-induced EMT by SOX4 targeting [60]. Other studies have been reported that miR-132-3p inhibited the lung and liver tumor cells invasions by SOX4 targeting [61, 62]. E2F5 belongs to the E2F family of transcription factors that regulate cell cycle progression [63]. It has been observed that there were significant miR-132 down regulation in ovarian tumor tissues and cell lines. It suppressed ovarian tumor cell proliferation and invasion via E2F5 targeting [64]. SIRT1 is an NAD dependent deacetylase that regulates cell death in oxidative and genotoxic stresses [65, 66]. SREBP is a leucine zipper transcription factor involved in cholesterogenesis and lipogenesis [67]. It has been observed that miR-132 reduced glioma cell proliferation by down regulations of SIRT1 and SREBP-1c [68]. CAMP-responsive element binding protein 5 (CREB5) is a zinc-finger DNA-binding protein with pivotal functions in cell proliferation and differentiation [69]. There was a significant SNHG5 up regulation in colorectal cancer (CRC) cells. It induced CRC invasion, while inhibited apoptosis through CREB5 up regulation following the miR-132-3p sponging [70].

EMT-related transcription factors

Enhancer of zeste homolog 2 (EZH2) is one of the components of Polycomb repressor complex 2 (PRC2) that is involved in DNA methylation using DNA methyl transferases (DNMTs) recruitment [71]. It has a pivotal role in epigenetic silencing by catalyzing the H3K27me3 in promoter sequences [72]. EZH2 is also up regulated by various transcription factors like SOX4 [73]. It has been reported that the SOX4/EZH2 complex induced H3K27me3 in miR-132 promoter sequence. MiR-132 reduced EMT process in ovarian tumor cells by CDH1 up regulation, while CDH2 and VIM down regulations. Therefore, SOX4 was suggested as the effector of miR-132 during EMT regulation in ovarian cancer (OC) [74]. BMI-1 is a ring finger component of PRC1 complex involved in epigenetic suppression [75]. It is an epigenetic modification protein involved in CSC self-renewal, tumor progression, and metastasis [21]. There were correlations between the BMI-1 up regulation, poor prognosis, increased invasion, and radio resistance [76, 77]. It was observed that there was miR-132 down regulation in cervical cancer. There was also a direct association between the levels of miR-132 expressions and radiation intensity. MiR-132 increased radio sensitivity through BMI-1 targeting [78]. It has been shown that there was significant miR-132 down regulation in SKOV3/CDDP cells compared with maternal SKOV3 cells. Reduced levels of miR-132 induced the CDDP resistance in ovarian tumor cells via BMI-1 targeting and subsequent apoptosis inhibition [79]. ZEB2 is a zinc finger transcription factor that functions as a transcriptional co-repressor via R-SMADs binding. There were significant SOX2OT up regulations in Non-small-cell lung carcinoma (NSCLC) tissues and cell lines. SOX2OT silencing significantly reduced cell proliferation, invasion, and EMT process by miR-132 sponging that resulted in ZEB2 up regulation [80]. There was also a significant miR-132 down-regulation in metastatic CRC tissues in comparison with non-metastatic tumor tissues. It reduced the CRC invasion and EMT process via ZEB2 targeting. The levels of miR-132 expressions were inversely correlated with stage, tumor size, survival, and distant metastasis in CRC patients [81].

Structural factors

USP9X belongs to the ubiquitin-specific peptidase (USP) family involved in various cellular processes via deubiquitinaton and stabilization of target proteins. USP9X up regulation is associated with tumor cell proliferation, drug resistance, and invasion [82]. It also deubiquitinates the MCL1 as an anti-apoptotic factor to suppress cell death in NSCLC [83]. It has been reported that miR-132 reduced NSCLC invasion via USP9X targeting [84]. USP22 belongs to the deubiquitinating enzyme (DUB) family of proteins involved in tumor relapse and progression [85]. USP22 silencing inhibits the tumor cell proliferation [76]. It has been reported that SNHG16 induced colorectal tumor cell proliferation and invasion through miR-132-3p sponging and subsequent USP22 up regulation [86]. HN1 promotes the ubiquitin-related degradation of b-catenin that results in loss of CDH1 interaction, actin organization, and cell migration [87]. It has been reported that there was miR-132 down regulation in breast cancer (BC) tissues in comparison with normal margins. MiR-132 significantly inhibited BC cell proliferation and metastasis through HN1 targeting. There was also a direct association between the levels of HN1 expression and poor survival in BC patients [23].

Derlin1 belongs to the derlin protein family that participates in endoplasmic reticulum (ER)-related degradation of misfolded proteins. It mediates retro translocation of misfolded proteins from ER to cytoplasm for the proteasomal degradation. Myocardial infarction associated transcript (MIAT) is an lncRNA associated with various human disorders such as diabetes and cancer [88]. There were significant MIAT up regulations in CRC tissues and cells. Silencing of MIAT promoted apoptosis, while suppressed CRC invasion. MIAT induced CRC cell proliferation and invasion through miR-132 sponging that resulted in Derlin-1 up regulation [89]. Tumor suppressor candidate 3 (TUSC3) is a component of the oligosaccharyl transferase complex involved in regulation of the N-linked protein glycosylation. It is a tumor suppressor frequently down regulated in different cancers. It has been reported that miR-132 promoted temozolomide resistance and glioblastoma initiating cells (GICs) phenotype formation by TUSC3 targeting in glioblastoma (GBM). TUSC3 also significantly down regulated the STAT3 and MDM2, while up regulate p53 [90].

TTK is a pivotal dual specificity kinase during mitotic checkpoint, centrosome duplication, and chromosome stability [91]. It induces cell proliferation and migration via AKT activation [92]. HLF is a transcription factor involved in resistance toward oxidative stress-induced apoptosis [93]. It has been reported that there were miR-132 down regulations in glioma tissues and cell lines that were associated with advanced tumor grades. HLF-mediated miR-132 inhibited glioma cell invasion and radio resistance via TTK inhibition [94]. P21-activated kinase 1 (Pak1) is a serine/threonine kinase that has key functions in cell migration, apoptosis, and neoplastic transformation [95, 96]. It regulates various cellular processes such as tumor cell invasion, drug resistance, angiogenesis, and EMT [97]. It exerts its oncogenic function by preventing apoptosis using different cascades including FOXO1, CLL/BCL-2, or DLC1 [98, 99]. ATF2 belongs to the b-ZIP family of transcription factors that regulates cellular differentiation and survival [100]. FN1 is an extracellular matrix glycoprotein involved in angiogenesis and tumor cell invasion [101]. It has been observed that miR-132 affected the hematogenous metastasis in GC. PAK1 down regulated the miR-132 via phosphorylation of ATF2 that prevents ATF2 to enter to the nucleus where it functions as an inducer of miR-132 expression. MiR-132 also reduced the levels of CD44 and FN1 expressions to promote lymphocytic mediated apoptosis of tumor cells. There were significant miR-132 down regulations in GC tissues that were associated with hematogenous metastasis. ATF2 up regulated the miR-132 that subsequently regulated the CD44/FN1/SIRT1/BDNF axis to recruit lymphocytes to suppress hematogenous metastasis in GC [102]. Receptor tyrosine kinases (RTKs) are the cell surface receptors for many extracellular signals such as hormones and growth factors. Aberrant RTK activation is implicated in progression of different tumors [103, 104]. MUC13 is a trans-membrane mucin associated with abnormal cell proliferation and tumor growth [105]. It activates the HER2, ERK, and AKT, while suppresses p53 expression [106]. It has been reported that there was a significant MUC13 up regulation in GC tissues in comparison with normal margins. MiR-132-3p suppressed GC progression by MUC13 targeting that resulted in activation of HER2 signaling [107].

Glucose transporter 1 (GLUT1) is a glucose uniporter across the erythrocytes plasma membranes. It has been shown that there was significant miR-132 down regulation in prostate tumor cells. MiR-132 silencing promoted the cell proliferation by induced glycolysis following the GLUT1 up regulation [108]. PEA-15 is an anti-apoptotic factor involved in TRAIL resistance of tumor cells. PEA15 over expression has been reported in GBM, leukemia, and NSCLC patients who were resistant against TRAIL [109,110,111]. MiR-132 reduced tumor cell proliferation and invasion, while increased apoptosis by targeting PEA-15 in astrocytoma. It was also observed that the miR-132 was regulated by CREB and KLF transcription factors [112]. Cyclin E1 (CCNE1) belongs to the cyclin family of proteins that regulates cyclin-dependent kinase 2 (CDK2) during cell cycle G1/S transition. It has been observed that there were miR-132 down regulations in OS tissues compared with normal bone tissues. MiR-132 reduced OS cell proliferation, colony formation, and in vivo growth via CCNE1 targeting [113].

PI3K/AKT pathway

The PI3K/AKT is an important signaling pathway that transfers the extracellular signals such as growth factors and hormones into the cells to regulate cell proliferation, metabolism, and apoptosis. PI3K activation by the RTKs and G-protein coupled receptors (GPCRs) subsequently phosphorylates and activates the AKT (Fig. 1). AKT is a serine/threonine kinase that has various effectors including CREB, FOXO, and mTOR [114, 115]. FOXO1 phosphorylation by AKT results in nuclear export and proteasome-dependent degradation [116]. It is a transcriptional regulator of apoptosis and CDK inhibitors such as BIM, FASL, p27, and p21 that inhibit G1/S transition and promote apoptosis [117, 118]. It has been reported that there was a significant miR-132 up regulation in laryngeal squamous cell carcinoma (LSCC) cells. MiR-132 promoted LSCC cell proliferation and tumor growth by PI3K/AKT activation and FOXO1 targeting [119]. PTEN as a tyrosine phosphatase inhibits the PI3K/AKT signaling by PIP3 dephosphorylation that results in AKT inhibition [120]. Therefore, PTEN down regulation activates the AKT/ERK pathway to regulate tumor cell proliferation and invasion. PTEN up regulation also promotes tumor cells apoptosis [121]. Moreover, it is a potent regulator of EMT progression [122]. It has been reported that there was miR-132 up regulation in pancreatic carcinoma that was associated with poor prognosis. MiR-132 reduced cell invasion and proliferation of pancreatic tumor cells through PTEN targeting [123]. MiR-132 increased doxorubicin resistance of BC cells through PTEN targeting [124]. Cold shock domain containing E1 (CSDE1) is an RNA binding protein (RBP) that is involved in tumor progression [125]. It has been observed that CSDE1 reduced thyroid tumor cell proliferation. CSDE1 down regulated the PTEN that resulted in AKT activation. MiR-132 also targeted the CSDE1 in thyroid tumor cells [126]. LAPTM4B is an inducer of tumor cell proliferation, invasion, and drug resistant by activation of PI3K/AKT pathway [127]. There were correlations between miR‐132‐3p down regulation, TNM staging, and tumor relapse in BC patients in which the patients with stage II/III had lower levels of miR-132-3p expressions compared with patients with stage I, and patients with recurrence had significantly lower levels of miR-132-3p expression. MiR‐132‐3p suppressed the breast tumor cell proliferation and invasion through LAPTM4B inhibition that resulted in inhibition of the PI3K/AKT/mTOR axis [128]. PIK3R3 is the regulatory subunit of the PI3K that phosphorylates phosphatidylinositol as a second messenger in intracellular signal transductions. It binds to the activated tyrosine kinases by SH2 domains to exert its functions. It has been reported that the LINC00160 knock down reduced the levels of PIK3R3 through miR-132 up regulation that resulted in reduced hepatocellular carcinoma (HCC) tumor cell drug resistance. There were also LINC00160 and PIK3R3 up regulations in HCC tissues. LINC00160 sponged the miR-132 to up regulate PIK3R3. LINC00160 silencing inhibited the HCC cell autophagy and proliferation, while induced apoptosis through PIK3R3 and ATG5 down regulations via promotion of miR-132 [129].

Fig. 1

Molecular mechanisms of miR-132 in regulation of PI3K/AKT and MAPK and signaling pathways during tumor progression

TGF-β pathway

Transforming growth factor b (TGF-β) is a secreted multi-faceted cytokine involved in regulation of embryogenesis, apoptosis, inflammation, and tissue homeostasis using SMAD family of transducer proteins. It triggers and maintains the EMT process by promotion of signaling pathways and transcription factors. Both SMAD-dependent and independent cascades are recruited by TGFβ to induce EMT during tumor progression. It has been reported that there was miR-132 down regulation in cervical cancer samples. MiR-132 reduced cervical tumor cell growth and invasion by SMAD2 targeting that resulted in EMT and cell cycle regulations. MiR-132 silencing promoted EMT via CDH1 down regulation, while VIM, FN1, SNAI1, SNAI2, and TWIST2 up regulations [130]. A significant miR-132 down regulation was also observed in BC tissues with metastatic lymph nodes. MiR-132 silencing promoted the breast tumor cell invasion and increased the levels of EMT-related markers and TGFβ1/SMAD2 expressions. There was an inverse association between SMAD2 and miR-132 expression levels in BC tissues. MiR-132 inhibited the EMT by down regulations of CDH2, ZEB1, SNAI1, and VIM in BC cells. It regulated the EMT process through TGFβ1/SMAD2 signaling pathway [131]. It has been observed that there was ILF3-AS1 up regulation in retinoblastoma (RB) tissues compared with normal controls. Levels of ILF3-AS1 expressions were directly correlated with advanced stage and optic nerve metastasis. ILF3-AS1 silencing significantly decreased malignant behaviors and in vivo tumor growth. ILF3-AS1 promoted RB progression through miR-132–3p sponging that up regulated the SMAD2 [132]. MiR-132 was reported to increase cisplatin sensitivity in Oral squamous cell carcinoma (OSCC) cells. There was also significant TGFβ1 up regulation in OSCC tissues that was conversely associated with miR-132 expression. MiR-132 also reduced OSCC cell proliferation and invasion by targeting the TGFβ1/SMAD2-3 axis [133]. Glucocorticoids are a class of corticosteroids with therapeutic values in lymphoid cancer, however some of the patients are insensitive to this treatment option [134]. Dexamethasone (DEX) is a glucocorticoid medication of tumor progression that promotes EMT and self-renewal via activation of the JNK and TGFβ pathways [135]. It has been observed that the DEX was involved in regulation of miR-132 promoter methylation. MiR-132 increased pancreatic tumor cell clonogenicity and EMT through TGFβ regulation [136].

Other signaling pathways

Mitogen-activated protein kinase (MAPK) signaling pathway is categorized to the ERK, JNK, and p38 cascades in mammalian cells which are involved in regulation of stress responses, cell proliferation, and differentiation. This signaling pathway transmits the extracellular signals via a sequential activation of MAP4K, MAP3K, and MAPKAPK. JNK and p38 are mainly activated in stress response, while the ERK1/2 are associated with cell proliferation and differentiation [137]. ERK1 is involved in tumor relapse, invasion, and drug resistance [138]. It can be regulated by the miR-132 during tumor progressions (Fig. 1). MiR-132 suppressed CRC cell proliferation and Adriamycin (ADM) resistance, while promoted apoptosis through ERK1 targeting [139]. There were XIST up regulations in CRC tissues and cells that were directly associated with TNM stage and tumor size. XIST induced colorectal tumor cell proliferation via the miR-132-3p/ERK2 axis [140]. Hedgehog (Hh) is a developmental signaling pathway involved in cell differentiation and embryogenesis. It is activated by Hh ligands binding with PTCH receptor that results in activation of GLI transcription factors [141]. Aberrant Shh activation induces the cell proliferation by Myc, PTCH, and CCND1 up regulations [142, 143]. It has been reported that miR-132 increased pancreatic tumor cell proliferation via Hh pathway [144]. Hippo signaling is involved in regulation of organ volume by the maintenance of cell proliferation/apoptosis balance [145, 146]. Yes-associated protein (YAP) is one of the key effectors of Hippo signaling pathway which has a pivotal function in induction of cell proliferation and invasion, while apoptosis suppression. It has been reported that miR-132 induced hepatoma cell apoptosis, while suppressed their proliferation and invasion through YAP targeting [147].

Conclusions

In present review we summarized all of the studies that have been evaluated the role of miR-132 in different cancers. This review clarifies the cell and molecular mechanisms that are regulated by miR-132 during tumor progressions. It has been reported that the miR-132 mainly functions as a tumor suppressor; it has also oncogenic functions especially in pancreatic tumors. It mainly exerts its roles during tumor progressions by regulation of the transcription factors and signaling pathways. Present review clarifies the tumor specific molecular mechanisms of miR-132 to introduce that as an efficient non-invasive diagnostic marker in various cancers.